Oarsman Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.9M Buy
2,061
+132
+7% +$134K 0.24% 68
2025
Q4
$2.07M Sell
1,929
-28
-1% -$26.8K 0.27% 66
2025
Q3
$1.49M Buy
1,957
+68
+4% +$50.6K 0.21% 79
2025
Q2
$1.47M Buy
1,889
+7
+0.4% +$5.44K 0.23% 84
2025
Q1
$1.55M Sell
1,882
-65
-3% -$54.1K 0.28% 76
2024
Q4
$1.5M Sell
1,947
-85
-4% -$70.4K 0.26% 76
2024
Q3
$1.8M Sell
2,032
-30
-1% -$27K 0.33% 61
2024
Q2
$1.87M Hold
2,062
0.41% 54
2024
Q1
$1.6M Sell
2,062
-525
-20% -$374K 0.38% 60
2023
Q4
$1.51M Buy
2,587
+732
+39% +$427K 0.4% 58
2023
Q3
$996K Hold
1,855
0.42% 65
2023
Q2
$870K Hold
1,855
0.38% 72
2023
Q1
$637K Hold
1,855
0.3% 81
2022
Q4
$679K Buy
1,855
+20
+1% +$7.09K 0.35% 76
2022
Q3
$593K Buy
1,835
+100
+6% +$31.7K 0.32% 83
2022
Q2
$563K Hold
1,735
0.28% 91
2022
Q1
$497K Hold
1,735
0.19% 115
2021
Q4
$479K Hold
1,735
0.19% 121
2021
Q3
$401K Hold
1,735
0.16% 137
2021
Q2
$398K Hold
1,735
0.16% 136
2021
Q1
$324K Buy
1,735
+375
+28% +$73.4K 0.14% 139
2020
Q4
$230K Sell
1,360
-50
-4% -$7.46K 0.09% 160
2020
Q3
$209K Hold
1,410
0.09% 158
2020
Q2
$231K Buy
+1,410
New +$216K 0.11% 143

Other funds holding LLY

Oarsman Capital's LLY Position: Q1 2026 in Review

Oarsman Capital increased its Eli Lilly (LLY) stake by 6.8% in Q1 2026, buying an estimated $134K and bringing the position to 2,061 shares worth $1.9M. The position accounts for 0.24% of the portfolio, ranked #68.

Oarsman Capital first reported a position in LLY in Q2 2020 and has held it in 24 quarters since. The position peaked at $2.07M in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Oarsman Capital held 2,061 shares of Eli Lilly worth $1.9M as of Q1 2026.
  • Oarsman Capital bought 132 Eli Lilly shares in Q1 2026, an estimated $134K.
  • Eli Lilly made up 0.24% of Oarsman Capital's portfolio in Q1 2026, its #68 holding.
  • Oarsman Capital first reported a position in Eli Lilly in Q2 2020 and has held it in 24 quarters since.
  • Oarsman Capital's Eli Lilly position peaked at $2.07M in Q4 2025.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Oarsman Capital's 13F filing for Q1 2026, filed 28 Apr 2026.